Back to search results

HALT Study: Blood Pressure Management in B-cell Cancers on BTKi Treatment

This study, called the HALT Study, is looking at how high blood pressure (hypertension) is managed and how to prevent heart-related problems in people with B-cell cancers like chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). You could join if you are starting a Bruton tyrosine kinase inhibitor (BTKi) treatment, which is a type of medicine that blocks certain proteins (kinases) in cancer cells. Researchers want to see how often new or worsening high blood pressure occurs and how it affects heart health over 12 months. This is an observational study, meaning you will receive standard care, and researchers will collect information about your health and treatment.

Study design
This is an observational study planning to enroll 100 participants. It is not a randomized study, and the phase is not specified.
What's involved
You would attend hypertension clinic visits, potentially have optional blood pressure monitoring, electrocardiograms, and impedance cardiography tests. Blood and urine samples would be collected, and your medical records reviewed.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, major adverse cardiovascular events (MACE), is measured for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06151730

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Recruiting
Not specifiedAll AgesObservational
Mayo Clinic
~100 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of major adverse cardiovascular events (MACE)
Measured over Up to 12 months

Conditions

Chronic Lymphocytic Leukemia
Hematopoietic and Lymphoid System Neoplasm
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Waldenstrom Macroglobulinemia

Explore related trials

Chronic Lymphocytic LeukemiaHematologic NeoplasmMantle Cell LymphomaMarginal Zone LymphomaWaldenstrom Macroglobulinemia

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Joerg Herrmann, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up

Exclusion

Patients with known central nervous system (CNS) involvement of their B-cell malignancy

What this trial measures

  • Incidence of major adverse cardiovascular events (MACE)Up to 12 months

    1-year MACE rates between patients with B-cell malignancies on BTKi with new or worsening HTN on optimal anti-HTN strategies will be compared with patients who do not develop HTN on BTKi.